Rankings / Cognitive — Prescription Stimulants
Vyvanse (lisdexamfetamine)
Cognitive · Prescription stimulant
Tier B-
High-risk evidence profile
Bottom line
Read Off Label grades Vyvanse (lisdexamfetamine) as B- (6.0/10) based on strong evidence, med-high benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Prodrug design reduces euphoria and injection misuse potential.
Studied, labeled, or reported-use context: 30-70 mg PO once daily morning — Rx; not individualized guidance.
Citation correction in progress
1 PubMed link was found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Prodrug design reduces euphoria and injection misuse potential. Also first FDA-approved drug for binge eating disorder. Same cardiovascular caution as Adderall. Generics now available in US.
Mechanism
L-lysine-conjugated d-amphetamine prodrug; cleaved in red blood cells to yield active d-amphetamine; smoother pharmacokinetics than Adderall with 10-14 hour duration
Studied, labeled, or reported dose & route
30-70 mg PO once daily morning
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Vyvanse (lisdexamfetamine)'s effects?
- Read Off Label rates the evidence for Vyvanse (lisdexamfetamine) as Strong and the benefit magnitude as med-high, producing an overall grade of B- (6.0/10). Prodrug design reduces euphoria and injection misuse potential.
- What safety findings are reported for Vyvanse (lisdexamfetamine)?
- Vyvanse (lisdexamfetamine) has a med-high risk profile in the database. Med-High (similar to Adderall; lower abuse potential due to prodrug) Legal status: Rx (Schedule II).
- What does the low Safety score for Vyvanse (lisdexamfetamine) represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Vyvanse (lisdexamfetamine)?
- 30-70 mg PO once daily morning This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Vyvanse (lisdexamfetamine) work?
- L-lysine-conjugated d-amphetamine prodrug; cleaved in red blood cells to yield active d-amphetamine; smoother pharmacokinetics than Adderall with 10-14 hour duration
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.